Companies
Phyton Biotech
produces paclitaxel by plant cell fermentation, advancing sustainable taxane bioproduction that decouples the API from yew-tree harvest.
- Country
- Germany
Commercial
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| wood-construction | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | Annual capacity of nearly 1,000 kg of crude paclitaxel in Germany; capacity to meet more than 1/3 of global demand for paclitaxel and docetaxel; worldwide facility capacity of 200,000 litres | phytonbiotech.com |
| Certification | Certificate of suitability (CEP) for paclitaxel API; cGMP certified facilities | phytonbiotech.com · fiercepharma.com |
| Regulatory approval | Inspected and certified by FDA, EMA, EDQM, TGA, PMDA, Health Canada, KFDA, and China's NMPA | phytonbiotech.com · fiercepharma.com |
| Production site | Ahrensburg, Germany and Vancouver, Canada | phytonbiotech.com · fiercepharma.com · pharmacompass.com |
| Headcount | Estimates range from 68 to 139 employees medium confidence | prospeo.io · datanyze.com |
| Revenue | Estimates range from $13 million to $21.5 million annually medium confidence | datanyze.com |
Independent sources: datanyze.com · fiercepharma.com · pharmacompass.com · prospeo.io
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Forest biopharma & phytochemicals | wood-construction | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.